Study details
Enrolling now
A Study on Bimekizumab in Breast Milk
UCB Biopharma SRL
NCT IDNCT06888193ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
20
Study length
about 1.5 years
Ages
18+
Sex
Female only
Locations
4 sites in CA, FL, NC +1
What this study is about
Researchers are testing how much bimekizumab, a medication, ends up in breast milk from mothers who are being treated with bimzelx®. The trial will last for 544 days and involve approximately 20 women.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Bimekizumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
bimekizumab
Endpoints
Secondary: Treatment-emergent Adverse Events (TEAEs) of the mother from time of informed consent through SFU contact
Body systems
Dermatology